January 31, 2026 10:14 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Delhi blast: Probe reveals doctors' module planned attacks on global coffee chain | Begging bowl: Pakistan PM says he feels “ashamed” seeking loans abroad | Epstein Files shocker! Zohran Mamdani’s mother Mira Nair mentioned in latest tranche | Bill Gates contracted STD after sex with Russian women? Epstein Files make explosive, unverified claims | Big setback for Modi govt: Supreme Court stays controversial UGC Equity Regulations 2026 amid student protests | ‘Mother of all deals’: PM Modi says India–EU FTA is for 'ambitious India' | Delhi HC snubs Sameer Wankhede’s defamation plea over Aryan Khan's Netflix series | Maharashtra in shock: Ajit Pawar dies in plane crash — funeral sees emotional gathering of political heavyweights | India, Canada eye 10-year uranium pact during PM Carney’s March visit | 'None will be harassed': Dharmendra Pradhan breaks silence as UGC rules trigger student protests

Australian university UNSW research holds out hope for thalassemia patients

| @indiablooms | Apr 06, 2018, at 10:11 pm

Sydney, Apr 6 (IBNS): Researchers at the University of New South Wales (UNSW) in Sydney, Australia, have used CRISPR gene editing technology to introduce beneficial natural mutations into blood cells to boost production of foetal haemoglobin.

The method could lead to new therapies for sickle cell anaemia and other blood disorders, says the university. The research solves a 50-year-old mystery about how these mutations -- which are naturally carried by a small percentage of people -- operate and alter the expression of human genes.

The details of the study, carried out by an international team led by UNSW scientist Professor Merlin Crossley, is published in the journal Nature Genetics.

Genome editing or gene editing give scientists the ability to change an organism's DNA. These technologies allow genetic material to be added, removed or altered at particular locations in the genome.

"Our new approach can be seen as a forerunner to 'organic gene therapy' for a range of common inherited blood disorders including beta thalassemia and sickle cell anaemia," said Professor Crossley, who is also UNSW Deputy Vice-Chancellor Academic.

"It is organic because no new DNA is introduced into the cells. Rather, we engineer in naturally occurring, benign mutations that are known to be beneficial to people with these conditions. It should prove to be a safe and effective therapy, although more research would be needed to scale the processes up into effective treatments," he added.

People with thalassemia or sickle-cell anaemia have defective adult haemoglobin -- the vital molecule that picks up oxygen in the lungs and transports it around the body -- and require life-long treatment with blood transfusions and medications.

According to UNSW, it has engaged in a series of initiatives with the Indian government, higher education institutions, and corporations for sharing and transfer of its vast pool of tech expertise. This sets UNSW apart from host of other institutions that see India as a one-way street to train Indian students.

UNSW is home to more than 52,000 students from nearly 130 count

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.